Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
-
Published:2024-05
Issue:3
Volume:23
Page:566-572
-
ISSN:1569-1993
-
Container-title:Journal of Cystic Fibrosis
-
language:en
-
Short-container-title:Journal of Cystic Fibrosis
Author:
Shi AlanORCID,
Nguyen HaroldORCID,
Kuo C. Benson,
Beringer Paul M.ORCID
Reference34 articles.
1. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del Allele;Middleton;N Engl J Med,2019
2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019
3. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial;Sutharsan;Lancet Respir Med,2022
4. Triple therapy for Cystic Fibrosis;Barry;N Engl J Med,2021
5. A phase 3 open-label study of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis and at least one;Zemanick;Am J Respir Crit Care Med,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献